143 related articles for article (PubMed ID: 11999646)
1. Effects of a novel class III antiarrhythmic agent, NIP-142, on canine atrial fibrillation and flutter.
Nagasawa H; Fujiki A; Fujikura N; Matsuda T; Yamashita T; Inoue H
Circ J; 2002 Feb; 66(2):185-91. PubMed ID: 11999646
[TBL] [Abstract][Full Text] [Related]
2. A multiple ion channel blocker, NIP-142, for the treatment of atrial fibrillation.
Tanaka H; Hashimoto N
Cardiovasc Drug Rev; 2007; 25(4):342-56. PubMed ID: 18078434
[TBL] [Abstract][Full Text] [Related]
3. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy.
Stambler BS; Wood MA; Ellenbogen KA
Circulation; 1997 Dec; 96(12):4298-306. PubMed ID: 9416896
[TBL] [Abstract][Full Text] [Related]
4. Ranolazine terminates atrial flutter and fibrillation in a canine model.
Bhimani AA; Yasuda T; Sadrpour SA; Khrestian CM; Lee S; Zeng D; Belardinelli L; Waldo AL
Heart Rhythm; 2014 Sep; 11(9):1592-9. PubMed ID: 25066042
[TBL] [Abstract][Full Text] [Related]
5. Termination of Atrial Flutter and Fibrillation by K201's Metabolite M-II: Studies in the Canine Sterile Pericarditis Model.
Sadrpour SA; Serhal M; Khrestian CM; Lee S; Fields T; Dittrich HC; Waldo AL
J Cardiovasc Pharmacol; 2015 May; 65(5):494-9. PubMed ID: 25636078
[TBL] [Abstract][Full Text] [Related]
6. The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model.
Rossman EI; Liu K; Morgan GA; Swillo RE; Krueger JA; Gardell SJ; Butera J; Gruver M; Kantrowitz J; Feldman HS; Petersen JS; Haugan K; Hennan JK
J Pharmacol Exp Ther; 2009 Jun; 329(3):1127-33. PubMed ID: 19252062
[TBL] [Abstract][Full Text] [Related]
7. Electrophysiologic and antiarrhythmic effects of the new class III antiarrhythmic drug KCB-328 in experimental canine atrial flutter.
Rahme MM; Ungab GA; Wadhwa M; Al-Kandari F; Yao B; Gupta A; Lee K; Kim HY; Feld GK
J Cardiovasc Pharmacol Ther; 2001 Jul; 6(3):297-306. PubMed ID: 11584336
[TBL] [Abstract][Full Text] [Related]
8. Characterization of in vivo and in vitro electrophysiological and antiarrhythmic effects of a novel IKACh blocker, NIP-151: a comparison with an IKr-blocker dofetilide.
Hashimoto N; Yamashita T; Tsuruzoe N
J Cardiovasc Pharmacol; 2008 Feb; 51(2):162-9. PubMed ID: 18287884
[TBL] [Abstract][Full Text] [Related]
9. Azd7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model.
Goldstein RN; Khrestian C; Carlsson L; Waldo AL
J Cardiovasc Electrophysiol; 2004 Dec; 15(12):1444-50. PubMed ID: 15610294
[TBL] [Abstract][Full Text] [Related]
10. Acute intravenous conversion of canine atrial flutter: comparison of antiarrhythmic agents.
Buchanan LV; Kabell G; Gibson JK
J Cardiovasc Pharmacol; 1995 Apr; 25(4):539-44. PubMed ID: 7596120
[TBL] [Abstract][Full Text] [Related]
11. Vanoxerine, a new drug for terminating atrial fibrillation and flutter.
Matsumoto N; Khrestian CM; Ryu K; Lacerda AE; Brown AM; Waldo AL
J Cardiovasc Electrophysiol; 2010 Mar; 21(3):311-9. PubMed ID: 19817929
[TBL] [Abstract][Full Text] [Related]
12. Oral vanoxerine prevents reinduction of atrial tachyarrhythmias: preliminary results.
Cakulev I; Lacerda AE; Khrestian CM; Ryu K; Brown AM; Waldo AL
J Cardiovasc Electrophysiol; 2011 Nov; 22(11):1266-73. PubMed ID: 21615815
[TBL] [Abstract][Full Text] [Related]
13. Effects of a new class III antiarrhythmic drug nibentan in a canine model of vagally mediated atrial fibrillation.
Fedorov VV; Sharifov OF; Beloshapko GG; Yushmanova AV; Rosenshtraukh LV
J Cardiovasc Pharmacol; 2000 Jul; 36(1):77-89. PubMed ID: 10892664
[TBL] [Abstract][Full Text] [Related]
14. Effects of antiarrhythmic drugs on canine atrial flutter due to reentry: role of prolongation of refractory period and depression of conduction to excitable gap.
Inoue H; Yamashita T; Nozaki A; Sugimoto T
J Am Coll Cardiol; 1991 Oct; 18(4):1098-104. PubMed ID: 1910060
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.
Nørgaard BL; Wachtell K; Christensen PD; Madsen B; Johansen JB; Christiansen EH; Graff O; Simonsen EH
Am Heart J; 1999 Jun; 137(6):1062-9. PubMed ID: 10347332
[TBL] [Abstract][Full Text] [Related]
16. Electrophysiologic effects of a new class III antiarrhythmic agent, E-4031, on atrial flutter, atrial refractoriness, and conduction delay in a canine sterile pericarditis model.
Shimizu A; Kaibara M; Centurion OA; Kapuku G; Hirata T; Fukatani M; Yano K; Hashiba K
J Cardiovasc Pharmacol; 1993 Apr; 21(4):656-62. PubMed ID: 7681913
[TBL] [Abstract][Full Text] [Related]
17. Electrophysiologic effects of SD-3212, a new class I antiarrhythmic drug, on canine atrial flutter and atrial action-potential characteristics.
Fujiki A; Tani M; Hayashi H; Mizumaki K; Inoue H; Uemura H; Nakaya H
J Cardiovasc Pharmacol; 1997 Apr; 29(4):471-5. PubMed ID: 9156356
[TBL] [Abstract][Full Text] [Related]
18. Electrophysiologic effects of the new class III antiarrhythmic drug dofetilide compared to the class IA antiarrhythmic drug quinidine in experimental canine atrial flutter: role of dispersion of refractoriness in antiarrhythmic efficacy.
Cha Y; Wales A; Wolf P; Shahrokni S; Sawhney N; Feld GK
J Cardiovasc Electrophysiol; 1996 Sep; 7(9):809-27. PubMed ID: 8884510
[TBL] [Abstract][Full Text] [Related]
19. Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide.
Wang J; Feng J; Nattel S
Circulation; 1994 Oct; 90(4):2032-40. PubMed ID: 7923691
[TBL] [Abstract][Full Text] [Related]
20. [Antiarrhythmic Efficacy of a New Class III Antiarrhythmic Drug RG-2.].
Fedorov VV; Rozenshtraukh LV; Reznik AV; Beloshapko GG; Iushmanova AV; Golitsyn SP; Ruda MIa; Chazov EI
Kardiologiia; 2004; 44(11):66-73. PubMed ID: 15602444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
